Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia

被引：28

作者：

Catuogno, M ^{[1
]}

Rezai, S ^{[1
]}

Priori, R ^{[1
]}

Magrini, L ^{[1
]}

Valesini, G ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Div Rheumatol, Rome, Italy

来源：

RHEUMATOLOGY | 2005年 / 44卷 / 03期

关键词：

D O I：

10.1093/rheumatology/keh470

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：406 / 406

页数：1

共 7 条

[1]

D'Arcy CA, 2001, ARTHRITIS RHEUM, V44, P1717, DOI 10.1002/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO

[2]

2-C

[3]

Grillo-López AJ, 1999, SEMIN ONCOL, V26, P66

[4] Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment [J].

Hellerstedt, B ;

Ahmed, A .

ANNALS OF ONCOLOGY, 2003, 14 (12) :1792-1792

[5] Rituximab-induced serum sickness [J].

Herishanu, Y .

AMERICAN JOURNAL OF HEMATOLOGY, 2002, 70 (04) :329-329

[6] Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20 [J].

Sansonno, D ;

De Re, V ;

Lauletta, G ;

Tucci, FA ;

Boiocchi, M ;

Dammacco, F .

BLOOD, 2003, 101 (10) :3818-3826

[7] Efficacy and safety of rituximab in type II mixed cryoglobulinemia [J].

Zaja, F ;

De Vita, S ;

Mazzaro, C ;

Sacco, S ;

Damiani, D ;

De Marchi, G ;

Michelutti, A ;

Baccarani, M ;

Fanin, R ;

Ferraccioli, G .

BLOOD, 2003, 101 (10) :3827-3834

← 1 →